Update on diagnosis and management of neoplastic pericardial disease

References

• Grebenc ML, Rosado de Christenson ML, Burke AP, et al. Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation. RadioGraphics. 2000;20:1073–1103.
   PubMed Web of Science ®Google Scholar
• Bussani R, De-Giorgio F, Abbate A, et al. Cardiac metastases. J Clin Pathol. 2007;60:27.
   PubMed Web of Science ®Google Scholar
• Lestuzzi C, Berretta M, Tomkowski W. 2015 update on the diagnosis and management of neoplastic pericardial disease. Expert Rev Cardiovasc Ther. 2015;13:377–389.
   PubMed Web of Science ®Google Scholar
• Lam K, Dickens P, Chan A. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993;117:1027–1031.
   PubMed Web of Science ®Google Scholar
• Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 1996;77:107.
   PubMed Web of Science ®Google Scholar
• Meng Q, Lai H, Lima J, et al. Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases. Int J Cardiol. 2002;84:69–75.
   PubMed Web of Science ®Google Scholar
• Patel J, Sheppard MN. Pathological study of primary cardiac and pericardial tumours in a specialist UK Centre: surgical and autopsy series. Cardiovasc Pathol. 2010;19:343–352.
   PubMed Web of Science ®Google Scholar
• Burazor I, Aviel-Ronen S, Imazio M, et al. Primary malignancies of the heart and pericardium: primary cardiac malignancies. Clin Cardiol. 2014. DOI:https://doi.org/10.1002/clc.22295
   Google Scholar
• Ramachandran R, Radhan P, Santosham R, et al. A rare case of primary malignant pericardial mesothelioma. J Clin Imaging Sci. 2014;4:47.
   PubMedGoogle Scholar
• Burazor I, Imazio M, Markel G, et al. Malignant pericardial effusion. Cardiology. 2013;124:224–232.
   PubMed Web of Science ®Google Scholar
• Restrepo CS, Vargas D, Ocazionez D, et al. Primary pericardial tumors. RadioGraphics. 2013;33:1613–1630.
   PubMed Web of Science ®Google Scholar
• Chetrit M, Xu B, Verma BR, et al. Multimodality imaging for the assessment of pericardial diseases. Curr Cardiol Rep. 2019;21:41.
   PubMed Web of Science ®Google Scholar
• Maleszewski JJ, Anavekar NS. Neoplastic pericardial disease. Cardiol Clin. 2017;35:589–600.
   PubMed Web of Science ®Google Scholar
• Burke A. Primary malignant cardiac tumors. Semin Diagn Pathol. 2008;25:39–46.
   PubMed Web of Science ®Google Scholar
• Lamba G, Frishman WH. Cardiac and pericardial tumors. Cardiol Rev. 2012;20:237–252.
   PubMed Web of Science ®Google Scholar
• Basso C, Valente M, Poletti A, et al. Surgical pathology of primary cardiac and pericardial tumors. Eur J Cardiothorac Surg. 1997;12:730–737.
   PubMed Web of Science ®Google Scholar
• Andreis A, Imazio M, de Ferrari GM. Contemporary diagnosis and treatment of recurrent pericarditis. Expert Rev Cardiovasc Ther. 2019;17:817–826.
   PubMed Web of Science ®Google Scholar
• Søgaard KK, Farkas DK, Ehrenstein V, et al. Pericarditis as a marker of occult cancer and a prognostic factor for cancer mortality. Circulation. 2017;136:996–1006.
   PubMed Web of Science ®Google Scholar
• Lestuzzi C. Epidemiology, diagnosis and therapy of neoplastic pericarditis. J Cardiovasc Echogr. 2011;21:86–91.
   Google Scholar
• Yared K, Baggish AL, Picard MH, et al. Multimodality imaging of pericardial diseases. JACC Cardiovasc Imaging. 2010;3:650–660.
   PubMed Web of Science ®Google Scholar
• Cosyns B, Plein S, Nihoyanopoulos P, et al. European association of cardiovascular imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging. 2014;16:12–31.
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European association of cardiovascular imaging and the American society of echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14:721–740.
   PubMed Web of Science ®Google Scholar
• Funari M, Fujita N, Peck W, et al. Cardiac tumors: assessment with Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15:953–958.
   PubMed Web of Science ®Google Scholar
• Kim M-S, Kim E-K, Choi JY, et al. Clinical utility of [18F]FDG-PET/CT in pericardial disease. Curr Cardiol Rep. 2019;21:107.
   PubMed Web of Science ®Google Scholar
• Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010;53:157–163.
   PubMed Web of Science ®Google Scholar
• Gavin FM, Gray C, Sutton J, et al. Morphometric differences between cytologically benign and malignant serous effusions. Acta Cytol. 1988;32:175–182.
   PubMed Web of Science ®Google Scholar
• Manosca F, Schinstine M, Fetsch PA, et al. Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol. 2007;35:6–11.
   PubMed Web of Science ®Google Scholar
• Tateishi K, Ikeda M, Yokoyama T, et al. Primary malignant sarcomatoid mesothelioma in the pericardium. Intern Med. 2013;52:249–253.
   PubMed Web of Science ®Google Scholar
• Shield PW, Koivurinne K. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology. 2008;19:218–223.
   PubMed Web of Science ®Google Scholar
• Lonardi S, Manera C, Marucci R, et al. Usefulness of claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol. 2011;39:313–317.
   PubMed Web of Science ®Google Scholar
• Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122:299–306.
   PubMed Web of Science ®Google Scholar
• Kao SC-H, Reid G, van Zandwijk N, et al. Molecular biomarkers in malignant mesothelioma: state of the art. Pathology. 2011;43:201–212.
   PubMed Web of Science ®Google Scholar
• Andersen M, Grauslund M, Ravn J, et al. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma. J Mol Diagn. 2014;16:418–430.
   PubMed Web of Science ®Google Scholar
• Paganuzzi M, Onetto M, Marroni P, et al. Diagnostic value of CYFRA 21–1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119:1138–1142.
   PubMed Web of Science ®Google Scholar
• Sundling KE, Cibas ES. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology. Cancer Cytopathol. 2018;126:590–598.
   PubMed Web of Science ®Google Scholar
• Gu P, Huang G, Chen Y, et al. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21:398–405.
   PubMed Web of Science ®Google Scholar
• Pohjola-Sintonen S, Tötterman KJ, Salmo M, et al. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer. 1987;60:31–37.
   PubMed Web of Science ®Google Scholar
• Karatolios K, Maisch B, Pankuweit S. [Tumor markers in the assessment of malignant and benign pericardial effusion]. Herz. 2011;36:290–295.
   PubMed Web of Science ®Google Scholar
• Karatolios K, Pankuweit S, Moosdorf RG, et al. Vascular endothelial growth factor in malignant and benign pericardial effusion. Clin Cardiol. 2012;35:377–381.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005;109:227–241.
   PubMed Web of Science ®Google Scholar
• Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86–91.
   PubMed Web of Science ®Google Scholar
• Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255–1262.
   PubMed Web of Science ®Google Scholar
• Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev. 2013;18:337–344.
   PubMed Web of Science ®Google Scholar
• Ristić AD, Pankuweit S, Maksimović R, et al. Pericardial cytokines in neoplastic, autoreactive, and viral pericarditis. Heart Fail Rev. 2013;18:345–353.
   PubMed Web of Science ®Google Scholar
• Pourel N, Santelmo N, Naafa N, et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response☆. Eur J Cardiothorac Surg. 2008;33:829–836.
   PubMed Web of Science ®Google Scholar
• Machtay M, Lee JH, Stevenson JP, et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg. 2004;127:108–113.
   PubMed Web of Science ®Google Scholar
• Petrella F, Radice D, Colombo N, et al. Pericardial-peritoneal window for malignant pericardial effusion. Shanghai Chest. 2018;2: 45–45.
   Google Scholar
• Imazio M. Dieci quesiti in tema di tamponamento cardiaco. G Ital Cardiol. 2018;19:8.
   Google Scholar
• Liu G, Crump M, Goss PE, et al. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol. 1996;14:3141–3147.
   PubMed Web of Science ®Google Scholar
• Maher EA, Shepherd FA, Todd TJ. Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg. 1996;112:637–643.
   PubMed Web of Science ®Google Scholar
• Kunitoh H, Tamura T, Shibata T, et al. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009;100:464–469.
   PubMed Web of Science ®Google Scholar
• Sugimoto JT, Little AG, Ferguson MK, et al. Pericardial window: mechanisms of efficacy. Ann Thorac Surg. 1990;50:442–445.
   PubMed Web of Science ®Google Scholar
• Swanson N, Mirza I, Wijesinghe N, et al. Primary percutaneous balloon pericardiotomy for malignant pericardial effusion. Cathet Cardiovasc Intervent. 2008;71:504–507.
   PubMed Web of Science ®Google Scholar
• Figoli F, Zanette ML, Tirelli U, et al. Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. Cancer Chemother Pharmacol. 1987;20:239–242.
   PubMed Web of Science ®Google Scholar
• Lerner-Tung MB, Chang AY, Ong LS, et al. Pharmacokinetics of intrapericardial administration of 5-fluorouracil. Cancer Chemother Pharmacol. 1997;40:318–320.
   PubMed Web of Science ®Google Scholar
• Casper ES, Kelsen DP, Alcock NW, et al. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983;67:235–238.
   PubMedGoogle Scholar
• Wang X, Zhou J, Wang Y, et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer. 2010;46:1474–1480.
   PubMed Web of Science ®Google Scholar
• Liu J, Meisner D, Kwong E, et al. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable Paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res. 2009;69:1174–1181.
   PubMed Web of Science ®Google Scholar
• Metro G, Lunardi G, Floridi P, et al. CSF Concentration of crizotinib in two ALK-positive non–small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 2015;10:e26–e27.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Kwak MH, Park S, et al. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat. 2010;42:210–216.
   PubMed Web of Science ®Google Scholar
• Çelik S, Lestuzzi C, Cervesato E, et al. Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. J Thorac Cardiovasc Surg. 2014;148:2288–2293.
   PubMed Web of Science ®Google Scholar
• Tomkowski WZ, Filipecki S. Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer. Lung Cancer. 1997;16:215–222.
   PubMed Web of Science ®Google Scholar
• Martinoni A, Cipolla CM, Cardinale D, et al. Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. CHEST. 2004;126:1412–1416.
   PubMed Web of Science ®Google Scholar
• Bischiniotis TS, Lafaras CT, Platogiannis DN, et al. Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J cardiol. 2005;46:324–329.
   PubMedGoogle Scholar
• Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis. IV [Internet]. 2018 [cited 2020 Aug 6];32. Available from: http://iv.iiarjournals.org/content/32/2/373.abstract
   Google Scholar
• Lestuzzi C, Bearz A, Lafaras C, et al. Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer. 2011;72:340–347.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391.
   PubMed Web of Science ®Google Scholar
• Nishino M, Sholl LM, Hatabu H, et al. Anti–PD-1–related pneumonitis during cancer immunotherapy. N Engl J Med. 2011;43(3):288–290.
   Google Scholar
• Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. Journal for ImmunoTherapy of Cancer. 2016;4(1):50.
   PubMedGoogle Scholar
• [cited 2020 Jun 11]. Available from: https://oncologypro.esmo.org/education-library/handbooks/oncological-emergencies/Malignant-Pericardial-Effusion-and-Cardiac-Tamponade.
   Google Scholar
• Buyukbayrak F, Aksoy E, Dedemoglu M, et al. Pericardiectomy for treatment of neoplastic constrictive pericarditis. Asian Cardiovasc Thorac Ann. 2014;22:296–300.
   PubMedGoogle Scholar
• Dempke W, Firusian N. Treatment of malignant pericardial effusion with 32P-colloid. Br J Cancer. 1999;80:1955–1957.
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Ueda N, Adachi H, et al. Long-term outcomes after video-assisted thoracoscopic pericardiectomy for pericardial effusion. Ann Thorac Cardiovasc Surg. 2017;23:304–308.
   PubMed Web of Science ®Google Scholar